Studies on tumor-bearing mouse models have demonstrated that (62, 63) multi-targeted anti-angiogenic tyrosine kinase inhibitors (TKIs) increased tumor infiltration of CD8+ and CD4+ T cells by downregulating PD-1 expression, and decreased the number and activity of Tregs and MDSCs (64). Here, CD8A is linked to neoplasm.